Abstract
Elemental impurities have been regulated in pharmaceutical products for many decades. Metal impurities such as As, Cd, Cu, Pb, Hg, V and Pt in pharmaceuticals and drugs are known to originate from sources like raw materials, catalysts, metal reagents and even manufacturing equipments. An account of the recent changes implemented by the European Pharmacopoeia (EP), the United States Pharmacopoeia (USP) and other International regulatory bodies for constraining inorganic impurities in pharmaceutical and drug products coupled with new strategies to be adopted for heavy metal analyses is presented. Rapid methods of screening during quality control operations, and a brief account of classical spectrophotometry and the role of instrumental techniques such as atomic absorption spectrometry (AAS), X-ray fluorescence spectrometry (XRF), instrumental neutron activation analysis (INAA), inductively coupled plasma atomic emission spectrometry (ICP-AES) and the inductively coupled plasma mass spectrometry (ICP-MS) for the accurate determination of inorganic impurities in pharmaceutical materials are presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.